NASDAQ · BRVE

Braveheart Bio, Inc.

Closing price · Nov 13, 2026 $19.62
Last insider buy · Aug 7, 2026 Paid by Director Christopher Viehbacher in an open-market buy (Form 4). $18.00

Latest quarter · ended Sep 30, 2026

Cash got weaker

descriptionFiled Nov 10, 2026
Cash from operationsWorse
−$24.4M
Quarter ended Sep 30, 2025: −$740K cash from operationsQuarter ended Sep 30, 2026: −$24.4M cash from operations
Sep '25Sep '26
vs. −$740K a year ago
Share countSteady
−0.2%
Quarter ended Mar 31, 2025: 90.04M sharesQuarter ended Jun 30, 2025: 90.04M sharesQuarter ended Sep 30, 2025: 90.04M sharesQuarter ended Mar 31, 2026: 90.04M sharesQuarter ended Jun 30, 2026: 90.04M sharesQuarter ended Sep 30, 2026: 89.87M shares
Mar '25Sep '26
89.87M shares vs. 90.04M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Mixed Insiders: as of Nov 13
−1000+100 0
  • info
    No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale
CEOCFOOther officersDirectorsDecJanFebMarAprMayJunJulAugSepOctNovCode C · Aug 7 · 18.26M sh · 2 peopleOpen-market buy · Aug 7 · $20KOpen-market buy · Aug 7 · $37.5M · 4 peopleOpen-market buy · Aug 7 · $1.5MOpen-market buy · Aug 7 · $500K
CEOCFOOther officersDirectorsJunJulAugSepOctNovCode C · Aug 7 · 18.26M sh · 2 peopleOpen-market buy · Aug 7 · $20KOpen-market buy · Aug 7 · $37.5M · 4 peopleOpen-market buy · Aug 7 · $1.5MOpen-market buy · Aug 7 · $500K

Last 6 months. A wider screen shows 12.

Showing 7 real trades. Bigger dot means a bigger trade.

Real trades, newest first

Aug 7 Erez Chimovits Director, 10% owner Open-market buy $34.9M 1,940,000 sh at $18.00
Aug 7 Travis Murdoch CEO and President, Director Open-market buy $1.5M 83,333 sh at $18.00
Aug 7 Christopher Viehbacher Director Open-market buy $1.5M 83,333 sh at $18.00
Aug 7 David Lubner Director Open-market buy $1000K 55,555 sh at $18.00
Aug 7 James Rickey CFO Open-market buy $500K 27,777 sh at $18.00
Aug 7 David Malek Director Open-market buy $75K 4,166 sh at $18.00
Aug 7 Michele Anderson Chief Development Officer Open-market buy $20K 1,111 sh at $18.00

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in BRVE

No 13F holdings loaded for this stock.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist